Clostridium Difficile

failure crash no fail rocket cancelled end
Biotech

Finch stops phase 3, lays off 95% of staff and plans asset sale

The microbiome biotech has decided to stop the study and seek to offload assets in the face of a frosty funding forecast and slow enrollment.
Nick Paul Taylor Jan 24, 2023 10:00am
C difficile clostridium difficile

Summit calls for antibiotic rethink after sharing trial data

Oct 21, 2022 9:51am
merger handshake

Morningside rolls up two biotechs to birth inflammation startup

Mar 10, 2022 9:30am
Pfizer sign

Pfizer fails C. diff vaccine test but sees possible way forward

Mar 1, 2022 8:20am